tbuckley/cabot-search huggingface dataset:
Suicide Mortality and Coronavirus Disease 2019—A Perfect Storm?
Authors: Mark A. Reger, Ian H. Stanley, Thomas E. Joiner
Journal: JAMA Psychiatry (2020)

Suicide rates have been rising in the US over the last 2 decades.The latest data available (2018) show the highest age-adjusted suicide rate in the US since 1941. 1 It is within this context that coronavirus disease 2019 (COVID-19) struck the US.Concerning disease models have led to historic and unprecedented public health actions to curb the spread of the virus.Remarkable social distancing interventions have been implemented to fundamentally reduce human contact.While these steps are expected to reduce the rate of new infections, the potential for adverse outcomes on suicide risk is high.Actions could be taken to mitigate potential unintended consequences on suicide prevention efforts, which also represent a national public health priority.
Pivotal Trial with Intravenous Plasminogen Replacement in Patients with Plasminogen Deficiency Demonstrates Long-Term Efficacy for Treatment and Prevention of Ligneous Lesions
Authors: Charles T Nakar, Joseph M Parker, Neelam Thakral, Brandon M. Hardesty, Gary Albert, Pierre Laurin, John Moran, Per Morten Sandset, Amy D. Shapiro
Journal: Blood (2017)
Legends of allergy and immunology: Jean Julien Raoul Bousquet; a Chemist, a Pharmacist, a Biologist, a Physician and—above all—an innovative scientist
Authors: Anna Bedbrook, Torsten Zuberbier
Journal: Allergy (2020)

Dr. Zuberbier reports personal fees from Bayer Health Care, FAES, Novartis, Henkel, Novartis and Henkel, and personal fees from AstraZeneca, AbbVie , ALK, Almirall, Astellas, Bayer Health Care, Bencard, Berlin Chemie, FAES, HAL, Leti, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, Teva, UCB, Henkel, Kryolan and L'Oréal Fee for talk, outside the submitted work.
The Influence of Exercise on Vascular Complications and Mortality Ii Patients with Type 2 Diabetes Mellitus
Authors: Juuso I Maekinen, Clara Chow, Sophia Zoungas, Stephen Harrap, Michel Marre, Bruce Neal, Neil Poulter, Anushka Patel, Mark Woodward, John Chalmers, Graham Hillis
Journal: Circulation (2012)
Abstract 11700: Higher Plasma EPA, EPA/AA and DHA Levels Are Associated With Lower Incident MACE Both in Those With and Without Angiographic CAD
Authors: Viet T Le, Kirk U Knowlton, Raymond O McCubrey, Stacey Knight, Mohit Jain, Jeramie D Watrous, Khoi Dao, Mahan Najhawan, Tami L Bair, Benjamin D Horne, Joseph B Muhlestein, Donald L Lappe, Madisyn Taylor, Jeffrey L Anderson
Journal: Circulation (2019)

Introduction: Omega-3 (OM3) supplementation has been advocated for cardiovascular disease prevention, but clinical trials have given mixed results. These divergent results may reflect differences i...
Comparison of Office-Based Physician Participation in Medicaid Managed Care and Health Insurance Exchange Plans in the Same US Geographic Markets
Authors: Jacob Wallace, Anthony Lollo, Chima D. Ndumele
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Several recent policy proposals have sought to expand the role of Medicaid in providing health insurance for low-income Americans, but there is little recent information on how physician participation in Medicaid compares with alternative forms of coverage for low-income Americans. <h3>Objective</h3> To compare the number of office-based physicians included in Medicaid managed care and health insurance exchange plans that operate in the same geographic markets. <h3>Design, Setting, and Participants</h3> This cross-sectional study used administrative data from physician network directories and survey data from office-based physicians for Kansas, Nebraska, New York, Tennessee, and Washington. The number of participants totaled 67 057 office-based physicians in the 5 sample states. Data were collected and analyzed from May 2018 to June 2019. <h3>Exposures</h3> Physician participation in a Medicaid managed care or health insurance exchange plan network. <h3>Main Outcomes and Measures</h3> The percentage of office-based physicians in a county who indicated during a phone survey that they participated in Medicaid; the percentage of office-based physicians in a county who participated in each Medicaid managed care and health insurance exchange plan network; and the percentage of office-based physicians in a county who participated in at least 1 Medicaid managed care plan or, separately, at least 1 health insurance exchange plan. <h3>Results</h3> Of the 67 057 office-based physicians in our sample, 49 983 reported in a telephone survey that they accepted Medicaid. This survey-based measure undercounted the percentage of physicians participating in Medicaid by 5.2% (95% CI, 2.3%-8.1%;<i>P</i> &lt; .001) relative to a measure based on physician network directories. Medicaid managed care physician networks covered a mean (SD) of 63.4% (20.5%) of office-based physicians compared with health insurance exchange physician networks, which covered 51.0% (25.2%). In adjusted analyses, Medicaid managed care plans covered 6.2% (95% CI, 3.2%-9.3%,<i>P</i> &lt; .001) more office-based physicians than health insurance exchange plans operating in the same counties. In the states where the same insurers participated in both markets (New York, Tennessee, Washington), the Medicaid managed care physician networks were 6.5% (95% CI, 3.2%-9.8%,<i>P</i> &lt; .001) larger than the health insurance exchange networks offered by the same insurer. <h3>Conclusions and Relevance</h3> In this cross-sectional study of physician network data, Medicaid managed care physician networks included more office-based physicians than the physician networks of health insurance exchange plans operating in the same geographic markets. This suggests that Medicaid remains a viable option for expanding coverage in the United States.
Abstract 16861: Neutrophils in Pulmonary Arterial Hypertension Show Heightened Elastase Along With Propensity to Form Extracellular Traps and an Antiviral Signature
Authors: Shalina Taylor, Aiqin Cao, Lingli Wang, Mingxia Gu, Kazuya Miyagawa, Marlene Rabinovitch
Journal: Circulation (2017)

Introduction: Patients with idiopathic pulmonary arterial hypertension (IPAH) have high circulating levels of neutrophil elastase (NE), and we have also observed low levels of the endogenous elasta...
Epidemiologic and Survival Trends in Amyloidosis, 1987–2019
Authors: Sriram Ravichandran, Helen J Lachmann, Ashutosh D Wechalekar
Journal: New England Journal of Medicine (2020)

Changes in Amyloidosis Epidemiology An analysis of 11,006 patients in the U.K. showed that the incidence of amyloidosis increased from 1967 to 2019. Light-chain amyloidosis was the most common type...
Combination therapy with ropivacaine-loaded liposomes and nutrient deprivation for simultaneous cancer therapy and cancer pain relief
Authors: Jiqian Zhang, Shasha Zhu, Qilian Tan, Dan Cheng, Qingqing Dai, Zhilai Yang, Lei Zhang, Fenfen Li, Youmei Zuo, Wei Dai, Lihai Chen, Erwei Gu, Guanghong Xu, Zhaolian Wei, Yunxia Cao, Xuesheng Liu
Journal: Theranostics (2020)

Autophagy allows cancer cells to respond changes in nutrient status by degrading and recycling non-essential intracellular contents.Inhibition of autophagy combined with nutrient deprivation is an effective strategy to treat cancer.Pain is a primary determinant of poor quality of life in advanced cancer patients, but there is currently no satisfactory treatment.In addition, effective treatment of cancer does not efficiently relieve cancer pain, but may increase pain in many cases.Hence, few studies focus on simultaneous cancer therapy and pain relief, and made this situation even worse.Method: Ropivacaine was loaded into tumor-active targeted liposomes.The cytotoxicity of ropivacaine-based combination therapy in B16 and HeLa cells were tested.Moreover, a mice model of cancer pain which was induced by inoculation of melanoma near the sciatic nerve was constructed to assess the cancer suppression and pain relief effects of ropivacaine-based combination therapy.Results: Ropivacaine and ropivacaine-loaded liposomes (Rop-DPRL) were novelly found to damage autophagic degradation.Replicated administration of Rop-DPRL and calorie restriction (CR) could efficiently repress the development of tumor.In addition, administration of Rop-DPRL could relieve cancer pain with its own analgestic ability in a short duration, while repeated administration of Rop-DPRL and CR resulted in continuous alleviation of cancer pain through reduction of VEGF-A levels in advanced cancer mice.Further, dual inhibition of phosphorylation of STAT3 at Tyr705 and Ser727 by Rop-DPRL and CR contribute to the reduction of VEGF-A.Conclusion: Combination therapy with Rop-DPRL and nutrient deprivation simultaneously suppresses cancer growth and relieves cancer pain.
Evaluation of Developmental Toxicity, Developmental Neurotoxicity, and Tissue Dose in Zebrafish Exposed to GenX and Other PFAS
Authors: Shaza Gaballah, Adam Swank, Jon R. Sobus, Xia Meng Howey, Judith Schmid, Tara Catron, James McCord, Erin Hines, Mark Strynar, Tamara Tal
Journal: Environmental Health Perspectives (2020)

BACKGROUND: Per-and polyfluoroalkyl substances (PFAS) are a diverse class of industrial chemicals with widespread environmental occurrence.Exposure to long-chain PFAS is associated with developmental toxicity, prompting their replacement with short-chain and fluoroether compounds.There is growing public concern over the safety of replacement PFAS.OBJECTIVE: We aimed to group PFAS based on shared toxicity phenotypes.METHODS: Zebrafish were developmentally exposed to 4,8-dioxa-3H-perfluorononanoate (ADONA), perfluoro-2-propoxypropanoic acid (GenX Free Acid), perfluoro-3,6-dioxa-4-methyl-7-octene-1-sulfonic acid (PFESA1), perfluorohexanesulfonic acid (PFHxS), perfluorohexanoic acid (PFHxA), perfluoro-n-octanoic acid (PFOA), perfluorooctanesulfonic acid (PFOS), or 0.4% dimethyl sulfoxide (DMSO) daily from 0-5 d post fertilization (dpf).At 6 dpf, developmental toxicity and developmental neurotoxicity assays were performed, and targeted analytical chemistry was used to measure media and tissue doses.To test whether aliphatic sulfonic acid PFAS cause the same toxicity phenotypes, perfluorobutanesulfonic acid (PFBS; 4-carbon), perfluoropentanesulfonic acid (PFPeS; 5-carbon), PFHxS (6-carbon), perfluoroheptanesulfonic acid (PFHpS; 7-carbon), and PFOS (8-carbon) were evaluated.RESULTS: PFHxS or PFOS exposure caused failed swim bladder inflation, abnormal ventroflexion of the tail, and hyperactivity at nonteratogenic concentrations.Exposure to PFHxA resulted in a unique hyperactivity signature.ADONA, PFESA1, or PFOA exposure resulted in detectable levels of parent compound in larval tissue but yielded negative toxicity results.GenX was unstable in DMSO, but stable and negative for toxicity when diluted in deionized water.Exposure to PFPeS, PFHxS, PFHpS, or PFOS resulted in a shared toxicity phenotype characterized by body axis and swim bladder defects and hyperactivity.CONCLUSIONS: All emerging fluoroether PFAS tested were negative for evaluated outcomes.Two unique toxicity signatures were identified arising from structurally dissimilar PFAS.Among sulfonic acid aliphatic PFAS, chemical potencies were correlated with increasing carbon chain length for developmental neurotoxicity, but not developmental toxicity.This study identified relationships between chemical structures and in vivo phenotypes that may arise from shared mechanisms of PFAS toxicity.These data suggest that developmental neurotoxicity is an important end point to consider for this class of widely occurring environmental chemicals.
Endothelial sodium channel activation promotes cardiac stiffness and diastolic dysfunction in Western diet fed female mice
Authors: James R. Sowers, Javad Habibi, Guanghong Jia, Brian Bostick, Camila Manrique-Acevedo, Guido Lastra, Yan Yang, Dongqing Chen, Zhe Sun, Timothy L. Domeier, William Durante, Adam T. Whaley-Connell, Michael A. Hill, Frederic Jaisser, Vincent G. DeMarco, Annayya R. Aroor
Journal: Metabolism (2020)
Hematological findings and complications of <scp>COVID</scp>‐19
Authors: Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, Ismail Elalamy, Efstathios Kastritis, Theodoros N. Sergentanis, Marianna Politou, Theodora Psaltopoulou, Grigoris Gerotziafas, Meletios A. Dimopoulos
Journal: American Journal of Hematology (2020)

Abstract COVID‐19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the disease course, longitudinal evaluation of lymphocyte count dynamics and inflammatory indices, including LDH, CRP and IL‐6 may help to identify cases with dismal prognosis and prompt intervention in order to improve outcomes. Biomarkers, such high serum procalcitonin and ferritin have also emerged as poor prognostic factors. Furthermore, blood hypercoagulability is common among hospitalized COVID‐19 patients. Elevated D‐Dimer levels are consistently reported, whereas their gradual increase during disease course is particularly associated with disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin degradation products increase, with severe thrombocytopenia lead to life‐threatening disseminated intravascular coagulation (DIC), which necessitates continuous vigilance and prompt intervention. So, COVID‐19 infected patients, whether hospitalized or ambulatory, are at high risk for venous thromboembolism, and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended. Last but not least, the need for assuring blood donations during the pandemic is also highlighted.
Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China
Authors: Ling Mao, Huijuan Jin, Mengdie Wang, Yu Hu, Shengcai Chen, Quanwei He, Jiang Chang, Candong Hong, Yifan Zhou, David Wang, Xiaoping Miao, Yanan Li, Bo Hu
Journal: JAMA Neurology (2020)

The outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, is serious and has the potential to become an epidemic worldwide. Several studies have described typical clinical manifestations including fever, cough, diarrhea, and fatigue. However, to our knowledge, it has not been reported that patients with COVID-19 had any neurologic manifestations.
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity
Authors: Álvaro Teijeira, Saray Garasa, María Gato, Carlos Alfaro, Itziar Migueliz, Assunta Cirella, Carlos de Andrea, Maria Carmen Ochoa, Itziar Otano, Iñaki Etxeberria, Maria Pilar Andueza, Celia P. Nieto, Leyre Resano, Arantza Azpilikueta, Marcello Allegretti, Maria de Pizzol, Mariano Ponz-Sarvisé, Ana Rouzaut, Miguel F. Sanmamed, Kurt Schalper, Michael Carleton, Mario Mellado, María E. Rodriguez-Ruiz, Pedro Berraondo, Jose L. Perez-Gracia, Ignacio Melero
Journal: Immunity (2020)
Dysregulated Sp1/miR-130b-3p/HOXA5 axis contributes to tumor angiogenesis and progression of hepatocellular carcinoma
Authors: Yadi Liao, Chenwei Wang, Zhiwen Yang, Wenwu Liu, Yichuan Yuan, Kai Li, Yuanping Zhang, Yongjin Wang, Yunxing Shi, Yuxiong Qiu, Dinglan Zuo, Wei He, Jiliang Qiu, Xinyuan Guan, Yunfei Yuan, Binkui Li
Journal: Theranostics (2020)

Angiogenesis, one of the hallmarks of cancer, is essential for both tumor growth and metastasis. However, its molecular mechanisms in hepatocellular carcinoma (HCC) are largely unknown. Here, we report the role of HOXA5 in tumor angiogenesis of HCC. Methods: The expression of miR-130b-3p and HOXA5 was determined by qRT-PCR and immunohistochemistry, respectively. Capillary tube formation assay, chicken chorioallantoic membrane assay, and subcutaneous xenograft experiments were performed to investigate the role of miR-130-3p and HOXA5. Luciferase reporter assay and chromatin immunoprecipitation assay were performed to evaluate the interaction between Sp1, miR-130b-3p and HOXA5. Results: miR-130b-3p was found up-regulated in HCC and correlated with a poor prognosis. miR-130b-3p promoted HCC angiogenesis both in vitro and in vivo. Mechanistically, HOXA5 was validated as a direct target of miR-130b-3p. Furthermore, we demonstrated that HOXA5 was down-regulated in HCC and its down-regulation was associated with larger tumor size, shorter overall survival, and higher recurrence probability. Moreover, HOXA5 was significantly associated with angiogenesis biomarkers such as CD31 and CD34. Functional studies revealed that the knockdown of HOXA5 also significantly promoted HCC angiogenesis both in vitro and in vivo. Knocking-down HOXA5 significantly provoked HCC cells to induce the capillary tube formation, migration and proliferation of endothelial cells. In xenograft animal models, we found that a decrease of HOXA5 effectively enhanced tumor growth and increased microvessel densities. We further demonstrated that miR-130b-3p could be directly transcriptionally regulated by Sp1. Conclusions: This study showed that a dysregulation in the Sp1/miR-130b-3p/HOXA5 axis contributed to HCC progression and angiogenesis, and that HOXA5 can be considered as a promising therapeutic target for treating HCC.
Means and ends of habitual action
Authors: Samantha Berthelette, Christopher Kalbach
Journal: Behavioral and Brain Sciences (2020)

Abstract Cushman claims that post hoc rationalization of habitual behavior can improve future reasoning. His characterization of habits includes two components: (1) habitual behavior is a non-rational process, and (2) habitual behavior is sometimes rationalized. We argue that Cushman fails to show any habits that are apt targets for rationalization. Thus, it's unclear when – if ever – rationalizing habits would improve reasoning.
Size profile of cell-free DNA: A beacon guiding the practice and innovation of clinical testing
Authors: Jiping Shi, Runling Zhang, Jinming Li, Rui Zhang
Journal: Theranostics (2020)

Cell-free DNA (cfDNA) has pioneered the development of noninvasive prenatal testing and liquid biopsy, its emerging applications include organ transplantation, autoimmune diseases, and many other disorders; size profile of cfDNA is a crucial biological property and is essential for its clinical applications.Therefore, a thorough mastery of the characteristic and potential applications of cfDNA size profile is needed.Methods: Based on the recent researches, we summarized the size profile of cfDNA in pregnant women, tumor patients, transplant recipients and systemic lupus erythematosus (SLE) patients to explore the common features.We also concluded the applications of size profile in pre-analytical phases, analytical phases for novel assays, and preparation of quality control materials (QCMs).Results: The size profile of cfDNA shared common features in different populations, and was distributed as a "ladder" pattern with a dominant peak at ~166 bp.However, cfDNA entailed slightly discrepant characteristics due to specific tissues of origin.The dominant peaks of fetal and maternal cfDNA fragments in pregnant women were at 143 bp and 166 bp, respectively.The plasma cfDNA in tumor patients, transplant recipients, and SLE patients had a peak of around 166 bp.In pre-analytical phases, size profile served as a vital indicator to judge the eligibility of specimens, thus ensuring the successful implementation of assays.More importantly, the size profile had the potential to enrich short fragments, calculate fetal fraction, detect fetal abnormalities, predict tumor progress in analytical phase and to guide the preparation of QCMs.Conclusions: Our finding summarized the characteristics and potential applications of cfDNA size profile, providing clinical researchers with novel assays by the extensive application of cfDNA.
Visualizing Speech-Generated Oral Fluid Droplets with Laser Light Scattering
Authors: Philip Anfinrud, Valentyn Stadnytskyi, Christina E. Bax, Adriaan Bax
Journal: New England Journal of Medicine (2020)

result on serum RT-qPCR assay for yellow fever.Liver-biopsy samples showed lobular necroinflammation, which included many foci of spotty necrosis, apoptosis, and hydropic hepatocyte degeneration in all lobular zones, without typical midzonal lesions associated with yellow fever, along with extensive hypercellularity and hypertrophy of Kupffer cells.Some of the patients had confluent necrosis.Among the patients who underwent liver biopsy, immunohistochemical analysis was positive for yellow fever antigen, which was found mainly in Kupffer-cell cytoplasm; such antigens are typically found in hepatocytes of the midzonal region in patients with acute yellow fever.All 26 patients recovered clinically with normal levels of liver enzymes.In a 2019 report, 5 researchers described rebound hepatitis associated with yellow fever in two travelers who had returned to France from Brazil.Similar to these investigators, we hypothesized that such cases of late-onset liver inflammation result from an impaired immune transition from an antiinflammatory pattern to a proinflammatory pattern owing to the presence of the virus or its antigens after the acute phase.In our study, the administration of sofosbuvir did not appear to be associated with subsequent changes in levels of liver enzymes.Thus, in this study, we characterized another possible clinical manifestation of yellow fever, a late-onset relapsing hepatitis occurring 1 to 4 months after the initial symptoms of severe acute yellow fever.Longer follow-up of the patients is needed to determine whether this condition will have serious health implications.
Visualization of the Human Intracranial Vasa Vasorum In Vivo Using Optical Coherence Tomography
Authors: Long Li, Adam A. Dmytriw, Timo Krings, Yiding Feng, Liqun Jiao
Journal: JAMA Neurology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal